These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 18408483)

  • 21. Prevention of heart failure.
    Bansal D; Chahoud G; Smith ES; Mehta JL
    Curr Opin Cardiol; 2006 Sep; 21(5):510-6. PubMed ID: 16900016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia.
    Gündogan K; Bayram F; Capak M; Tanriverdi F; Karaman A; Ozturk A; Altunbas H; Gökce C; Kalkan A; Yazici C
    Metab Syndr Relat Disord; 2009 Oct; 7(5):427-34. PubMed ID: 19754305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The metabolic syndrome: how to approach differing definitions.
    Pi-Sunyer X
    Med Clin North Am; 2007 Nov; 91(6):1025-40, vii. PubMed ID: 17964907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004.
    Nguyen NT; Magno CP; Lane KT; Hinojosa MW; Lane JS
    J Am Coll Surg; 2008 Dec; 207(6):928-34. PubMed ID: 19183541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of societal changes on patterns of urolithiasis.
    Zilberman DE; Yong D; Albala DM
    Curr Opin Urol; 2010 Mar; 20(2):148-53. PubMed ID: 19940772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal stone disease and obesity: what is important for urologists and nephrologists?
    Ahmed MH; Ahmed HT; Khalil AA
    Ren Fail; 2012; 34(10):1348-54. PubMed ID: 23013150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The metabolic syndrome: in need of a global mission statement.
    Cameron AJ; Zimmet PZ; Shaw JE; Alberti KG
    Diabet Med; 2009 Mar; 26(3):306-9. PubMed ID: 19317827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beware the low urine pH--the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes.
    Bell DS
    Diabetes Obes Metab; 2012 Apr; 14(4):299-303. PubMed ID: 21992452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
    Cannon CP
    Am J Cardiol; 2008 Dec; 102(12A):5L-9L. PubMed ID: 19084083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
    Reasner CA
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emerging link between hypogonadism and metabolic syndrome.
    Guay AT
    J Androl; 2009; 30(4):370-6. PubMed ID: 18772486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cascade of events -- obesity, metabolic syndrome, and type 2 diabetes mellitus in youth.
    McGillis Bindler RC
    Nurs Clin North Am; 2007 Mar; 42(1):29-42, vi. PubMed ID: 17270588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of prehypertension for metabolic syndrome, diabetes, and coronary heart disease among Turks.
    Onat A; Yazici M; Can G; Kaya Z; Bulur S; Hergenç G
    Am J Hypertens; 2008 Aug; 21(8):890-5. PubMed ID: 18551102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey.
    Kjeldsen SE; Naditch-Brule L; Perlini S; Zidek W; Farsang C
    J Hypertens; 2008 Oct; 26(10):2064-70. PubMed ID: 18806632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic syndrome: diabetes and cardiovascular disease.
    Gupta S; Gupta BM
    Indian Heart J; 2006; 58(2):149-52. PubMed ID: 18989060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasis as the marker of underlying systemic disease.
    Kourosh AS; Miner A; Menter A
    Skin Therapy Lett; 2008 Feb; 13(1):1-5. PubMed ID: 18357363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The new epidemiology of nephrolithiasis.
    Shoag J; Tasian GE; Goldfarb DS; Eisner BH
    Adv Chronic Kidney Dis; 2015 Jul; 22(4):273-8. PubMed ID: 26088071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of chronic and end stage kidney disease in patients with nephrolithiasis.
    Shoag J; Halpern J; Goldfarb DS; Eisner BH
    J Urol; 2014 Nov; 192(5):1440-5. PubMed ID: 24929140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management.
    Sakhaee K; Maalouf NM; Sinnott B
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1847-60. PubMed ID: 22466339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of the metabolic syndrome in pediatrics: a blessing and a curse.
    Battista M; Murray RD; Daniels SR
    Semin Pediatr Surg; 2009 Aug; 18(3):136-43. PubMed ID: 19573755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.